



# Metabolite Ligands

for Focused-Target

aladdin<sup>®</sup>

# Preamble

---

In the multifaceted world of modern biochemistry, no domain has taken on as much significance as the complex interplay between ligands and their respective biological targets. This realm of interactions, at once minute in scale and massive in impact, is the cornerstone of countless biochemical processes and, indeed, life itself.

This handbook is designed to serve as a comprehensive guide to the study of ligands used for targets. Our aim is to provide readers with a profound understanding of the myriad aspects of ligand-target interactions, including the molecular intricacies, the physiological implications, and the therapeutic potential of these biochemical duos.

Ligands are entities, typically small molecules, proteins, or ions, which bind to specific targets, usually proteins such as receptors, ion channels, or enzymes, within organisms. The result of this binding action can be the modulation of the target's function, leading to an array of physiological effects, from signal transmission and immunological response to hormonal regulation and beyond. Not only are ligand-target interactions vital for normal biological function, but they also hold immense potential for therapeutic interventions.

In this handbook, we delve into the underlying principles of ligand-target interaction, exploring topics from fundamental biochemistry to advanced pharmacodynamics. We seek to illuminate how these interactions are integral to drug discovery and development processes, providing the scaffold for the creation of therapeutic strategies to combat a host of medical conditions.


We hope this handbook serves not only as a tool for learning but also as a catalyst for innovative thought, encouraging readers to explore and expand the boundaries of what we currently understand about ligands and their targets. The complex dance of molecular interaction waits for no one; it is our privilege to invite you to join in this exploration, to comprehend, and perhaps even to influence the rhythm of life.

As we embark on this journey through the world of ligands and targets, let us remember that the secrets of life are often found in the smallest of interactions. With the right understanding and application, these minute phenomena have the potential to instigate seismic shifts in our approach to health and disease.



# Catalogue

1. Activator
2. Agonist
3. Allosteric modulator
4. Antagonist
5. Channel blocker
6. Gating inhibitor
7. Inhibitor
8. Subunit-specific
9. Others



# Activator

Target	Cat.No	CAS	Product Name	Specification	Type	Action
AMP kinase	A136967	61-19-8	5'-Adenylic Acid	≥98.0%(HPLC)	Activator	Activation
ASIC3	L465637	9008-30-4	L-α-Lysophosphatidylcholine from egg yolk	≥99%, Type I, powder	Activator	Partial agonist
carbonic anhydrase 1	E113174	51-43-4	L(-)-Epinephrine	98%	Activator	Activation
carbonic anhydrase 1,5A,7	H111796	51-45-6	Histamine, Free Base	96%	Activator	Activation
carbonic anhydrase 1,14,5A,7	H108261	71-00-1	L-Histidine	EP,USP, from non-animal source,for cell culture	Activator	Activation
CatSper1,2,3,4	P129960	745-65-3	Prostaglandin E1	≥98%(HPLC)	Activator	Full agonist
CatSper1,2,3,4	D133402	363-24-6	Dinoprostone	98%	Activator	Full agonist
CatSper1,2,3,4	P336179	745-62-0	PGF1α (Prostaglandin F1α)	98%	Activator	Full agonist
CatSper1,2,3,4	P106427	57-83-0	Progesterone	USP grade	Activator	Full agonist
CIC-2	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Others
CNGA1,2,3	G349525	7665-99-8	Guanosine 3',5'-cyclic monophosphate	≥98%	Activator	Agonist
CNGA2,3	C107047	60-92-4	Adenosine 3',5'-cyclic monophosphate	99%	Activator	Agonist
HCN1,2	C107047	60-92-4	Adenosine 3',5'-cyclic monophosphate	99%	Activator	Agonist
HCN2	G349525	7665-99-8	Guanosine 3',5'-cyclic monophosphate	≥98%	Activator	Agonist
IP <sub>3</sub> R1	A501266	56-65-5	Adenosine triphosphate	90%	Activator	Others
IP <sub>3</sub> R1,2,3	P486700	142656-03-9	Poly(Disperse Red 13 acrylate)	-	Activator	Others
K <sub>2p</sub> 10.1,13.1	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Others
K <sub>2p</sub> 10.1	D100925	6217-54-5	Cervonic Acid	≥98%	Activator	Others
K <sub>2p</sub> 10.1	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Activator	Others
K <sub>2p</sub> 10.1	L465637	9008-30-4	L-α-Lysophosphatidylcholine from egg yolk	≥99%, Type I, powder	Activator	Others
K <sub>2p</sub> 16.1,2.1	C153359	26675-46-7	1-Chloro-2,2,2-trifluoroethyl Difluoromethyl Ether	>98.0%(GC)	Activator	Others
K <sub>2p</sub> 2.1	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Activation
K <sub>2p</sub> 2.1,3.1	C153359	26675-46-7	1-Chloro-2,2,2-trifluoroethyl Difluoromethyl Ether	>98.0%(GC)	Activator	Positive
K <sub>2p</sub> 4.1	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Others
K <sub>2p</sub> 4.1	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Positive
K <sub>ca</sub> 1.1	E110147	50-28-2	β-Estradiol	analytical standard, 99.5%	Activator	Others
K <sub>ca</sub> 2.3,3.4	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Agonist
K <sub>ca</sub> 3.1,3.2,3.4	E111989	64-17-5	Ethanol	Analytical Reagent, water≤0.3%	Activator	Agonist

# Activator

Target	Cat.No	CAS	Product Name	Specification	Type	Action
K <sub>v</sub> 6.1	A501266	56-65-5	Adenosine triphosphate	90%	Activator	Agonist
K <sub>v</sub> 2.1	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Activator	Others
L-Phenylalanine hydroxylase	T305191	17528-72-2	Tetrahydrobiopterin	≥98%	Activator	Activation
phosphodiesterase 2A	G349525	7665-99-8	Guanosine 3',5'-cyclic monophosphate	≥98%	Activator	Activation
PLD2	O108486	112-80-1	Oleic acid	analytical standard, ≥99.0%(GC)	Activator	Activation
protein kinase C zeta	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Activation
RyR1,2,3	A501266	56-65-5	Adenosine triphosphate	90%	Activator	Others
TPC1,2	L385596	-	L-α-Phosphatidyl-D-myo-inositol 3,5-diphosphate, dipalmitoyl	-	Activator	Activation
TRPA1	H274882	75899-68-2	4-Hydroxynonenal	≥97%	Activator	Activation
TRPA1	O274680	103560-62-9	4-Oxo-2-nonenal (4-ONE)	≥98%	Activator	Activation
TRPA1	A433552	75-07-0	Acetaldehyde	ACS reagent, ≥99.5%	Activator	Activation
TRPA1	D100925	6217-54-5	Cervonic Acid	≥98%	Activator	Activation
TRPA1	C153359	26675-46-7	1-Chloro-2,2,2-trifluoroethyl Difluoromethyl Ether	>98.0%(GC)	Activator	Activation
TRPA1	M109036	78-98-8	Methylglyoxal	32% solution	Activator	Activation
TRPA1	P275095	13345-50-1	Prostaglandin A2	≥98%	Activator	Activation
TRPA1	M105139	89-78-1	DL-Menthol	analytical standard	Activator	Partial agonist
TRPC2	S397171	60514-48-9	1,2-Dioctanoyl-sn-glycerol	≥96%	Activator	Agonist
TRPC2	S347974	65914-84-3	1-Stearoyl-2-arachidonoyl-sn-glycerol	≥95%	Activator	Agonist
TRPC5	M420133	83-43-2	6-α-Methylprednisolone Solution	analytical standard, 100 ng/ul in Acetonitrile	Activator	Activation
TRPC5,6	L465637	9008-30-4	L-α-Lysophosphatidylcholine from egg yolk	≥99%, Type I, powder	Activator	Others
TRPC6	S347974	65914-84-3	1-Stearoyl-2-arachidonoyl-sn-glycerol	≥95%	Activator	Agonist
TRPC6	S336173	34487-26-8	1-Stearoyl-2-linoleoyl-sn-glycerol	≥98%	Activator	Agonist
TRPC6	H126988	79551-86-3	20-HETE	≥90%(HPLC)	Activator	Others
TRPC6	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Others
TRPC7	S397171	60514-48-9	1,2-Dioctanoyl-sn-glycerol	≥96%	Activator	Agonist
TRPM2	N348628	5502-96-5	Nicotinic acid adenine dinucleotide phosphate sodium salt	≥92%	Activator	Agonist
TRPM2	N432853	53-84-9	β-Nicotinamide adenine dinucleotide hydrate	≥95% (HPLC)	Activator	Agonist
TRPM2	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Activator	Potentiation

# Activator

Target	Cat.No	CAS	Product Name	Specification	Type	Action
TRPM3	D130610	764-22-7	D-erythro-sphinganine	>99%	Activator	Agonist
TRPM3	D130604	123-78-4	D-erythro-sphinganine	>99%	Activator	Agonist
TRPM8	M105139	89-78-1	DL-Menthol	analytical standard	Activator	Others
TRPM8	M105139	89-78-1	DL-Menthol	analytical standard	Activator	Partial agonist
TRPML1,2,3	L385596	-	L- $\alpha$ -Phosphatidyl-D-myo-inositol 3,5-diphosphate, dipalmitoyl	-	Activator	Activation
TRPP2	C108872	77-92-9	Citrate	analytical standard	Activator	Agonist
TRPP2	D433329	6915-15-7	DL-Malic acid	Pharmaceutical GMP grade, Ph. Eur., NF, FCC, E 296	Activator	Agonist
TRPV1	A274932	94421-68-8	Anandamide (ethanol solution)	$\geq 98\%$	Activator	Activation
TRPV1	H336047	71774-10-2	12(S)-HPETE	50 $\mu\text{g/ml}$ in ethanol, $\geq 98\%$	Activator	Agonist
TRPV1	H342777	71774-08-8	5(S)-HPETE	50 $\mu\text{g/ml}$ in ethanol	Activator	Agonist
TRPV1	A274932	94421-68-8	Anandamide (ethanol solution)	$\geq 98\%$	Activator	Agonist
TRPV1	A288783	128007-31-8	Arvanil	$\geq 98\%$ (HPLC)	Activator	Agonist
TRPV1	L275630	71160-24-2	Leukotriene B4	$\geq 99\%$	Activator	Agonist
TRPV1	H336630	70608-72-9	5(S)-HETE	50 $\mu\text{g/ml}$ in ethanol	Activator	Others
TRPV2	L465637	9008-30-4	L- $\alpha$ -Lysophosphatidylcholine from egg yolk	$\geq 99\%$ , Type I, powder	Activator	Activation
TRPV3	M105139	89-78-1	DL-Menthol	analytical standard	Activator	Activation
TRPV4	A111764	506-32-1	Arachidonic acid	analytical standard, $\geq 99.0\%$ (GC)	Activator	Activation
TRPV4	C108872	77-92-9	Citrate	analytical standard	Activator	Agonist
TRPV6	A433552	75-07-0	Acetaldehyde	ACS reagent, $\geq 99.5\%$	Activator	Activation
TRPV6	E111989	64-17-5	Ethanol	Analytical Reagent, water $\leq 0.3\%$	Activator	Activation

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
Androgen receptor	A101162	63-05-8	<b>4-Androstene-3,17-dione</b>	<b>analytical standard, <math>\geq 99\%</math></b>	<b>Agonist</b>	<b>Agonist</b>
GABA <sub>B</sub> , GABA <sub>B1</sub> receptor	A104200	56-12-2	<b><math>\gamma</math>-Aminobutyric acid</b>	<b>99%</b>	<b>Agonist</b>	<b>Full agonist</b>
Glycine Receptor (All subtypes)	A104200	56-12-2	<b><math>\gamma</math>-Aminobutyric acid</b>	<b>99%</b>	<b>Agonist</b>	<b>Partial agonist</b>
GluN1,2A,2B,2C,2D	A105951	1783-96-6	<b>D-Aspartic acid</b>	<b>98%</b>	<b>Agonist</b>	<b>Agonist</b>
Adenosine A1,A2A, A2B,A3 receptor	A108808	58-61-7	<b>Adenosine</b>	<b>Ultra pure,99.5%</b>	<b>Agonist</b>	<b>Agonist</b>
GluN1,2A2B,2C,2D	A110750	56-40-6	<b>Aminoacetic acid</b>	<b>analytical standard</b>	<b>Agonist</b>	<b>Agonist</b>
Glycine Receptor (All subtypes)	A110750	56-40-6	<b>Aminoacetic acid</b>	<b>analytical standard</b>	<b>Agonist</b>	<b>Agonist</b>
GPRC6 receptor	A110750	56-40-6	<b>Aminoacetic acid</b>	<b>analytical standard</b>	<b>Agonist</b>	<b>Full agonist</b>
GPRC6 receptor	A118651	74-79-3	<b>L-Arginine</b>	<b>from non-animal source, meets EP, USP specifications, suitable for cell culture, 98.5-101.0%</b>	<b>Agonist</b>	<b>Full agonist</b>
P2Y <sub>1</sub> ,P2Y <sub>12</sub> ,P2Y <sub>13</sub> receptor	A119474	58-64-0	<b>Adenosine 5'-diphosphate</b>	<b><math>\geq 95\%</math> (HPLC)</b>	<b>Agonist</b>	<b>Full agonist</b>
P2Y <sub>11</sub> receptor	A119474	58-64-0	<b>Adenosine 5'-diphosphate</b>	<b><math>\geq 95\%</math> (HPLC)</b>	<b>Agonist</b>	<b>Agonist</b>
P2Y <sub>6</sub> receptor	A119474	58-64-0	<b>Adenosine 5'-diphosphate</b>	<b><math>\geq 95\%</math> (HPLC)</b>	<b>Agonist</b>	<b>Partial agonist</b>
GluN1,2A,2B,2C,2D	A137730	56-84-8	<b>L-Aspartic acid</b>	<b>98%</b>	<b>Agonist</b>	<b>Agonist</b>
Glycine Receptor (All subtypes)	A137901	107-95-9	<b><math>\beta</math>-Alanine</b>	<b>98%</b>	<b>Agonist</b>	<b>Partial agonist</b>
MRGPRD	A137901	107-95-9	<b><math>\beta</math>-Alanine</b>	<b>98%</b>	<b>Agonist</b>	<b>Agonist</b>
MRGPRD	A137901	107-95-9	<b><math>\beta</math>-Alanine</b>	<b>98%</b>	<b>Agonist</b>	<b>Full agonist</b>
CB <sub>1</sub> receptor	A274643	229021-64-1	<b>ACPA (Arachidonylcyclopropylamide)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Full agonist</b>
GPR18	A274643	229021-64-1	<b>ACPA (Arachidonylcyclopropylamide)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Agonist</b>
CB <sub>1</sub> ,CB <sub>2</sub> receptor	A274932	94421-68-8	<b>Anandamide (ethanol solution)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Partial agonist</b>
GPR18	A274932	94421-68-8	<b>Anandamide (ethanol solution)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Full agonist</b>
GPR55	A274932	94421-68-8	<b>Anandamide (ethanol solution)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Agonist</b>
GPR18	A275341	179113-91-8	<b>N-Arachidonylglycine (NAGly)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Agonist</b>
GPR18	A275341	179113-91-8	<b>N-Arachidonylglycine (NAGly)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Full agonist</b>
LPA <sub>5</sub> receptor	A275341	179113-91-8	<b>N-Arachidonylglycine (NAGly)</b>	<b><math>\geq 98\%</math></b>	<b>Agonist</b>	<b>Partial agonist</b>
FFA2,FFA3 receptor	A433225	64-19-7	<b>Acetic acid 96%</b>	<b>Premium-Grade Reagents, for Analysis</b>	<b>Agonist</b>	<b>Full agonist</b>
GPR17	A501266	56-65-5	<b>Adenosine triphosphate</b>	<b>90%</b>	<b>Agonist</b>	<b>Agonist</b>
P2X1,2,3,4,5,6,7	A501266	56-65-5	<b>Adenosine triphosphate</b>	<b>90%</b>	<b>Agonist</b>	<b>Agonist</b>

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
P2Y <sub>1</sub> ,P2Y <sub>4</sub> receptor	A501266	56-65-5	Adenosine triphosphate	90%	Agonist	Partial agonist
P2Y <sub>11</sub> ,P2Y <sub>13</sub> ,P2Y <sub>2</sub> receptor	A501266	56-65-5	Adenosine triphosphate	90%	Agonist	Full agonist
P2Y <sub>4</sub> receptor	A501266	56-65-5	Adenosine triphosphate	90%	Agonist	Agonist
FFA2,FFA3 receptor	B110439	107-92-6	Butyric acid	Standard for GC, >99.5%(GC)	Agonist	Full agonist
HCA <sub>2</sub> receptor	B110439	107-92-6	Butyric acid	Standard for GC, >99.5%(GC)	Agonist	Agonist
Glucocorticoid receptor	B121764	378-44-9	Betamethasone Solutiom	1.00mg/ml	Agonist	Full agonist
Adenosine A1,A2A, A3 receptor	C103231	146-77-0	2-Chloroadenosine	99%	Agonist	Agonist
Adenosine A1,A2A, A2B,A3 receptor	C103231	146-77-0	2-Chloroadenosine	99%	Agonist	Full agonist
Farnesoid X receptor	C103692	81-25-4	Cholic acid	analytical standard, >98%	Agonist	Agonist
GPBA receptor	C103692	81-25-4	Cholic acid	analytical standard, >98%	Agonist	Full agonist
RAR-related orphan receptor- $\alpha$	C104029	57-88-5	Cholesterol	analytical standard, 99.0%	Agonist	Agonist
Farnesoid X receptor	C104903	474-25-9	Chenodeoxycholic acid	analytical standard	Agonist	Agonist
GPBA receptor	C104903	474-25-9	Chenodeoxycholic acid	analytical standard	Agonist	Full agonist
Farnesoid X receptor- $\beta$	C105355	67-97-0	Cholecalciferol (D3)	analytical standard	Agonist	Agonist
GPRC6 receptor	C109228	372-75-8	L-Citrulline	98%	Agonist	Full agonist
Glucocorticoid receptor	C119329	50-22-6	Corticosterone	analytical standard	Agonist	Agonist
Mineralocorticoid receptor	C119329	50-22-6	Corticosterone	analytical standard	Agonist	Agonist
Vitamin D receptor	C120126	32222-06-3	calcitriol	97%	Agonist	Agonist
GPR183	C130176	2140-46-7	cholest-5-ene-3,25-diol	>99%	Agonist	Agonist
RAR-related orphan receptor- $\gamma$	C130176	2140-46-7	cholest-5-ene-3,25-diol	>99%	Agonist	Agonist
GPR183	C130177	20380-11-4	cholest-(25R)-5-ene-3 $\beta$ ,27-diol	>99%	Agonist	Agonist
Liver X receptor- $\alpha,\beta$	C130177	20380-11-4	cholest-(25R)-5-ene-3 $\beta$ ,27-diol	>99%	Agonist	Agonist
GPR183	C130186	566-26-7	cholest-5-en-3 $\beta$ ,7 $\alpha$ -diol	>98%	Agonist	Agonist
GPR183	C130187	566-27-8	7 $\beta$ -Hydroxycholesterol	>99%	Agonist	Agonist
Farnesoid X receptor	C130203	22348-64-7	cholest-5-ene-3 $\beta$ ,22(S)-diol	>99%	Agonist	Agonist
Liver X receptor- $\alpha,\beta$	C130203	22348-64-7	cholest-5-ene-3 $\beta$ ,22(S)-diol	>99%	Agonist	Agonist
Liver X receptor- $\alpha,\beta$	C130207	474-73-7	cholest-5-ene-3 $\beta$ ,22(S)-diol	>99%	Agonist	Agonist



# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
stimulator of interferon response cGAMP interactor 1	C413868	1441190-66-4	2',3'-cGAMP Sodium Salt	98%	Agonist	Agonist
Retinoic acid receptor- $\alpha,\beta,\gamma$	C432837	5300-03-8	9-cis-Retinoic acid	$\geq 98\%$ (HPLC)	Agonist	Agonist
Retinoid X receptor- $\alpha,\beta,\gamma$	C432837	5300-03-8	9-cis-Retinoic acid	$\geq 98\%$ (HPLC)	Agonist	Agonist
FFA1 receptor	D100925	6217-54-5	Cervonic Acid	$\geq 98\%$	Agonist	Full agonist
Retinoid X receptor- $\alpha$	D100925	6217-54-5	Cervonic Acid	$\geq 98\%$	Agonist	Agonist
Farnesoid X receptor	D103698	83-44-3	Deoxycholic acid	analytical standard, $>99\%$	Agonist	Agonist
GPBA receptor	D103698	83-44-3	Deoxycholic acid	analytical standard, $>99\%$	Agonist	Full agonist
TAAR5	D106273	598-56-1	N,N-Dimethylethylamine	99%	Agonist	Full agonist
Estrogen receptor- $\alpha,\beta$	D109025	56-53-1	Diethylstilbestrol	99%	Agonist	Agonist
GPR84	D109189	334-48-5	Decanoic acid	Standard for GC, $>99\%$ (GC)	Agonist	Full agonist
GPR143	D111049	59-92-7	L-dopa	analytical standard, $>99\%$	Agonist	Agonist
Vitamin D receptor	D120130	54573-75-0	Doxercalciferol	98%	Agonist	Agonist
GPR183	D130181	240129-43-5	7 $\beta$ ,27-dihydroxycholesterol	$>99\%$	Agonist	Agonist
GPR183	D130221	64907-22-8	7 $\alpha$ ,25-dihydroxycholesterol	$>98\%$	Agonist	Full agonist
GPR1,2,3,6,63	D130606	26993-30-6	D-erythro-sphingosine-1-phosphate	$\geq 98.0\%$	Agonist	Full agonist
P2RY10	D130606	26993-30-6	D-erythro-sphingosine-1-phosphate	$\geq 98.0\%$	Agonist	Agonist
S1P <sub>1</sub> ,S1P <sub>2</sub> ,S1P <sub>3</sub> ,S1P <sub>4</sub> ,S1P <sub>5</sub> receptor	D130606	26993-30-6	D-erythro-sphingosine-1-phosphate	$\geq 98.0\%$	Agonist	Agonist
DP <sub>1</sub> ,DP <sub>2</sub> receptor	D133402	363-24-6	Dinoprostone	98%	Agonist	Full agonist
EP <sub>1</sub> ,EP <sub>2</sub> ,EP <sub>3</sub> ,EP <sub>4</sub> receptor	D133402	363-24-6	Dinoprostone	98%	Agonist	Full agonist
FP receptor	D133402	363-24-6	Dinoprostone	98%	Agonist	Full agonist
TP receptor	D133402	363-24-6	Dinoprostone	98%	Agonist	Full agonist
Glucocorticoid receptor	D133972	64-85-7	11-Deoxy Corticosterone	$\geq 97\%$ (HPLC)	Agonist	Agonist
Mineralocorticoid receptor	D133972	64-85-7	11-Deoxy Corticosterone	$\geq 97\%$ (HPLC)	Agonist	Agonist
Alpha-2B adrenoceptor	D274858	329-65-7	DL-Adrenaline (Racpinephrine)	98%	Agonist	Partial agonist
Alpha-2C adrenoceptor	D274858	329-65-7	DL-Adrenaline (Racpinephrine)	98%	Agonist	Full agonist
Beta-1,Beta-3 adrenoceptor	D274858	329-65-7	DL-Adrenaline (Racpinephrine)	98%	Agonist	Full agonist
EP <sub>4</sub> receptor	D274858	19313-28-1	13,14-Dihydroprostaglandin E1	$\geq 98\%$	Agonist	Full agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
EP <sub>2</sub> ,EP <sub>4</sub> receptor	D275015	39746-25-3	<b>16,16-Dimethylprostaglandin E2, 15-hydroxy PGDH inhibitor</b>	≥98%	Agonist	Full agonist
EP <sub>3</sub> receptor	D275015	39746-25-3	<b>16,16-Dimethylprostaglandin E2, 15-hydroxy PGDH inhibitor</b>	≥98%	Agonist	Partial agonist
Peroxisome proliferator-activated receptor-γ	D275807	87893-55-8	<b>15-Deoxy-Delta12</b>	≥97%	Agonist	Full agonist
Peroxisome proliferator-activated receptor-γ	D276527	1927-31-7	<b>2'-Deoxyadenosine 5'-triphosphate [dATP] trisodium salt trihydrate</b>	≥98%	Agonist	Full agonist
EP <sub>2</sub> ,EP <sub>3</sub> ,EP <sub>4</sub> receptor	D334664	37786-00-8	<b>11-deoxy Prostaglandin E1</b>	≥96%	Agonist	Full agonist
EP <sub>3</sub> receptor	D334664	37786-00-8	<b>11-deoxy Prostaglandin E1</b>	≥96%	Agonist	Partial agonist
EP <sub>4</sub> receptor	D334664	37786-00-8	<b>11-deoxy Prostaglandin E1</b>	≥96%	Agonist	Agonist
Glucocorticoid receptor	D336852	382-67-2	<b>Desoximetasone</b>	≥98%	Agonist	Agonist
DP <sub>2</sub> receptor	D355691	85235-11-6	<b>15-deoxy-δ12,14-Prostaglandin D2</b>	A solution in methyl acetate	Agonist	Full agonist
DP <sub>2</sub> receptor	D356084	27376-76-7	<b>13,14-Dihydro-15-keto -prostaglandin F2α</b>	A solution in methyl acetate, ≥95%	Agonist	Full agonist
Androgen receptor	D413176	521-18-6	<b>Dihydrotestosterone (DHT)</b>	98%	Agonist	Agonist
D <sub>1</sub> ,D <sub>2</sub> ,D <sub>3</sub> ,D <sub>4</sub> ,D <sub>5</sub> receptor	D590946	51-61-6	<b>Dopamine</b>	95%	Agonist	Full agonist
Estrogen receptor-α,β	E105514	50-27-1	<b>Estriol</b>	analytical standard	Agonist	Agonist
Estrogen receptor-α,β	E105516	53-16-7	<b>Estrone</b>	analytical standard	Agonist	Agonist
Estrogen receptor-α,β	E110147	50-28-2	<b>β-Estradiol</b>	analytical standard, 99.5%	Agonist	Agonist
GPER	E110147	50-28-2	<b>β-Estradiol</b>	analytical standard, 99.5%	Agonist	Full agonist
Pregnane X receptor	E110147	50-28-2	<b>β-Estradiol</b>	analytical standard, 99.5%	Agonist	Agonist
Alpha-1A,1B,1D, 2A adrenoceptor	E113174	51-43-4	<b>L(-)-Epinephrine</b>	98%	Agonist	Full agonist
Alpha-2B,2C adrenoceptor	E113174	51-43-4	<b>L(-)-Epinephrine</b>	98%	Agonist	Agonist
Beta-1,3 adrenoceptor	E113174	51-43-4	<b>L(-)-Epinephrine</b>	98%	Agonist	Agonist
Beta-2 adrenoceptor	E113174	51-43-4	<b>L(-)-Epinephrine</b>	98%	Agonist	Full agonist
Estrogen receptor-α,β	E129595	57-63-6	<b>Ethinyl Estradiol</b>	≥98%	Agonist	Agonist
Peroxisome proliferator-activated receptor-α	E274770	1191-85-1	<b>5,8,11,14-Eicosatetraynoic acid</b>	≥98%	Agonist	Agonist
BLT2 receptor	E349093	83709-73-3	<b>12-epi Leukotriene B4</b>	A solution in ethanol	Agonist	Partial agonist
Glucocorticoid receptor	H110523	50-23-7	<b>Hydrocortisone</b>	98%	Agonist	Agonist
Mineralocorticoid receptor	H110523	50-23-7	<b>Hydrocortisone</b>	98%	Agonist	Agonist
H <sub>1</sub> ,H <sub>2</sub> ,H <sub>3</sub> ,H <sub>4</sub> receptor	H111796	51-45-6	<b>Histamine, Free Base</b>	96%	Agonist	Full agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
GPR84	H275247	1883-13-2	3-Hydroxydodecanoic acid	≥98%	Agonist	Full agonist
BLT2 receptor	H276042	54845-95-3	15(S)-HETE	≥99%	Agonist	Partial agonist
GPR84	H276183	2984-55-6	2-Hydroxydodecanoic acid	≥98%	Agonist	Full agonist
GPR84	H276520	5393-81-7	2-Hydroxydecanoic acid	≥98%	Agonist	Full agonist
5-HT <sub>1A</sub> ,5-HT <sub>1B</sub> ,5-HT <sub>1D</sub> , 5-HT <sub>1E</sub> ,5-HT <sub>1F</sub> ,5-HT <sub>2A</sub> , 5-HT <sub>2B</sub> ,5-HT <sub>2C</sub> ,5-HT <sub>4</sub> , 5-HT <sub>5A</sub> ,5-HT <sub>6</sub> ,5-HT <sub>7</sub> receptor	H303833	50-67-9	5-Hydroxytryptamine	≥98% (HPLC)	Agonist	Full agonist
5-HT <sub>3A</sub>	H303833	50-67-9	5-Hydroxytryptamine	≥98% (HPLC)	Agonist	Agonist
5-HT <sub>3AB</sub>	H303833	50-67-9	5-Hydroxytryptamine	≥98% (HPLC)	Agonist	Agonist
D <sub>1</sub> receptor	H303833	50-67-9	5-Hydroxytryptamine	≥98% (HPLC)	Agonist	Partial agonist
D <sub>5</sub> receptor	H303833	50-67-9	5-Hydroxytryptamine	≥98% (HPLC)	Agonist	Full agonist
GPR132	H336037	73543-67-6	9(S)-HODE	A solution in ethanol, ≥98%	Agonist	Full agonist
OXE receptor	H336630	70608-72-9	5(S)-HETE	50 µg/ml in ethanol	Agonist	Full agonist
BLT2 receptor	H336636	54397-84-1	12(S)-HHT	50-100 µg/ml in ethanol	Agonist	Full agonist
OXE receptor	H342777	71774-08-8	5(S)-HPETE	50 µg/ml in ethanol	Agonist	Full agonist
Peroxisome proliferator-activated receptor-α	H342781	98462-03-4	8(S)-HETE	50 µg/ml in ethanol	Agonist	Agonist
BLT2 receptor	H342782	54397-83-0	12(S)-HETE	A solution in ethanol, >98%	Agonist	Partial agonist
GPR31	H342782	54397-83-0	12(S)-HETE	A solution in ethanol, >98%	Agonist	Full agonist
Farnesoid X receptor-β	H400267	313-04-2	3β-hydroxy-5,24-cholestadiene	>99%	Agonist	Agonist
Liver X receptor-α,β	H400267	313-04-2	3β-hydroxy-5,24-cholestadiene	>99%	Agonist	Agonist
FFA2,FFA3 receptor	I103521	79-31-2	Isobutyric acid	Standard for GC, ≥99.5%(GC)	Agonist	Full agonist
TAAR3	I103521	107-85-7	Isopentylamine	99%	Agonist	Full agonist
oxoglutarate receptor	K105570	328-50-7	α-Ketoglutaric acid	99%,for cell culture	Agonist	Full agonist
GPR35	K120012	492-27-3	Kynurenic acid	97%	Agonist	Agonist
FFA1,FFA4 receptor	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Agonist	Full agonist
Hepatocyte nuclear factor-4-α	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Agonist	Full agonist
Peroxisome proliferator-activated receptor-γ	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Agonist	Full agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
GPRC6 receptor	L103479	56-87-1	L-Lysine	98%	Agonist	Full agonist
FFA1,FFA4 receptor	L105575	463-40-1	Linolenic acid	99%	Agonist	Full agonist
Farnesoid X receptor	L106779	434-13-9	Lithocholic acid	>97.0%	Agonist	Agonist
GPBA receptor	L106779	434-13-9	Lithocholic acid	>97.0%	Agonist	Full agonist
Pregnane X receptor	L106779	434-13-9	Lithocholic acid	>97.0%	Agonist	Agonist
Vitamin D receptor	L106779	434-13-9	Lithocholic acid	>97.0%	Agonist	Agonist
HCA <sub>1</sub> receptor	L107595	79-33-4	L-Lactic Acid	80%	Agonist	Full agonist
GPR84	L110739	143-07-7	Lauric acid	standard for GC, ≥99.5%(GC)	Agonist	Agonist
Farnesoid X receptor-β	L130208	79-63-0	Lanosterol	>99%	Agonist	Agonist
CysLT <sub>1</sub> ,CysLT <sub>2</sub> receptor	L274987	75715-89-8	Leukotriene E4	≥98%	Agonist	Partial agonist
GPR17	L274987	75715-89-8	Leukotriene E4	≥98%	Agonist	Agonist
CysLT <sub>1</sub> ,CysLT <sub>2</sub> receptor	L275222	72025-60-6	Leukotriene C4	≥98%	Agonist	Full agonist
GPR17	L275222	72025-60-6	Leukotriene C4	≥98%	Agonist	Agonist
BLT1 receptor	L275630	71160-24-2	Leukotriene B4	≥99%	Agonist	Full agonist
BLT2 receptor	L275630	71160-24-2	Leukotriene B4	≥99%	Agonist	Partial agonist
Peroxisome proliferator-activated receptor-α	L275630	71160-24-2	Leukotriene B4	≥99%	Agonist	Agonist
FPR2/ALX	L342353	171030-11-8	Lipoxin A4, 15-epi	Solution in ethanol, >98%	Agonist	Full agonist
FPR2/ALX,FPR3	L345922	89663-86-5	Lipoxin A4	A solution in ethanol, ≥95%	Agonist	Full agonist
FPR2/ALX	L345922	89663-86-5	Lipoxin A4	A solution in ethanol, ≥95%	Agonist	Partial agonist
GPR32	L345922	89663-86-5	Lipoxin A4	A solution in ethanol, ≥95%	Agonist	Full agonist
GPRC6 receptor	L413185	70-26-8	L-Ornithine	95%	Agonist	Full agonist
GPRC6 receptor	L432949	56-85-9	L-Glutamine	Pharmaceutical GMP grade DAB,USP	Agonist	Full agonist
CysLT <sub>1</sub> ,CysLT <sub>2</sub> receptor	L490624	73836-78-9	Leukotriene D4	98%,100mg/ml	Agonist	Full agonist
GPR17	L490624	73836-78-9	Leukotriene D4	98%,100mg/ml	Agonist	Agonist
MT <sub>1</sub> ,MT <sub>2</sub> receptor	M118674	73-31-4	Melatonin	98%	Agonist	Full agonist
GPBR	M125960	362-07-2	2-Methoxyestradiol (2-MeOE2)	≥98%	Agonist	Agonist
Vitamin D receptor	M127999	103909-75-7	Maxacalcitol	≥98%	Agonist	Agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
PAF receptor	M275051	91575-58-5	MethylcarbamyI-PAF	≥98%	Agonist	Agonist
Glucocorticoid receptor	M420133	83-43-2	6- $\alpha$ -Methylprednisolone Solution	analytical standard, 100 ng/ul in Acetonitrile	Agonist	Agonist
FFA1,FFA4 receptor	M432884	544-63-8	Myristic acid	for synthesis	Agonist	Full agonist
nucleotide binding oligomerization domain containing 1	M465023	922-54-3	meso-2,6-Diaminopimelic acid	≥98% (TLC)	Agonist	Agonist
TA <sub>1</sub> receptor	M474350	582-22-9	$\beta$ -Methylphenethylamine	99%	Agonist	Agonist
HCA <sub>1</sub> receptor	N103654	59-67-6	Nicotinic acid	analytical standard, ≥99.5% (HPLC)	Agonist	Agonist
HCA <sub>2</sub> ,HCA <sub>3</sub> receptor	N103654	59-67-6	Nicotinic acid	analytical standard, ≥99.5% (HPLC)	Agonist	Full agonist
Alpha-1A,1B,1D,2A, 2C adrenoceptor	N109573	51-41-2	L-Noradrenaline	98%	Agonist	Full agonist
Alpha-2B adrenoceptor	N109573	51-41-2	L-Noradrenaline	98%	Agonist	Partial agonist
Beta-1,2 adrenoceptor	N109573	51-41-2	L-Noradrenaline	98%	Agonist	Agonist
Beta-3 adrenoceptor	N109573	51-41-2	L-Noradrenaline	98%	Agonist	Full agonist
GPR119	N135851	544-31-0	Palmitoylethanolamide	≥98%	Agonist	Full agonist
GPR55	N135851	544-31-0	Palmitoylethanolamide	≥98%	Agonist	Agonist
GPR55	N276283	222723-55-9	Noladin ether	≥98%	Agonist	Agonist
P2Y <sub>11</sub> receptor	N348628	5502-96-5	Nicotinic acid adenine dinucleotide phosphate sodium salt	≥92%	Agonist	Full agonist
P2Y <sub>11</sub> receptor	N432853	53-84-9	$\beta$ -Nicotinamide adenine dinucleotide hydrate	≥95% (HPLC)	Agonist	Full agonist
TA <sub>1</sub> receptor	O101521	770-05-8	( $\pm$ )-Octopamine hydrochloride	98%	Agonist	Full agonist
FFA1,FFA4 receptor	O108486	112-80-1	Oleic acid	analytical standard, ≥99.0%(GC)	Agonist	Full agonist
PAF receptor	O130783	74389-68-7	1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine	>99%	Agonist	Full agonist
OXE receptor	O275056	106154-18-1	5-Oxoete (5-Ketoeicosa-6E,8Z,11Z, 14E-tetraenoic acid)	≥95%	Agonist	Full agonist
GPR119	O287241	105955-11-1	OLDA	≥99%(HPLC)	Agonist	Agonist
Pregnane X receptor	O351925	1553-56-6	3-Oxo-5 $\beta$ -cholanoic Acid	-	Agonist	Agonist
Vitamin D receptor	O351925	1553-56-6	3-Oxo-5 $\beta$ -cholanoic Acid	-	Agonist	Agonist
BLT1 receptor	O353437	79516-82-8	20-OH-LTB4	50 $\mu$ g/ml in ethanol, ≥99%	Agonist	Full agonist
FFA1 receptor	P101058	57-10-3	Palmitic acid	analytical standard, >99%(GC)	Agonist	Full agonist
TA <sub>1</sub> receptor	P105641	64-04-0	$\beta$ -phenylethylamine	98%	Agonist	Full agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
TAAR4P	P105641	64-04-0	<b>β-phenylethylamine</b>	98%	Agonist	Agonist
TAAR4P	P105641	64-04-0	<b>β-phenylethylamine</b>	98%	Agonist	Partial agonist
Progesterone receptor	P106427	57-83-0	<b>Progesterone</b>	USP grade	Agonist	Agonist
HCA <sub>3</sub> receptor	P109094	673-06-3	<b>D-Phenylalanine</b>	98%	Agonist	Full agonist
GPR139	P110424	63-91-2	<b>L-Phenylalanine</b>	99%	Agonist	Agonist
FFA2,FFA3 receptor	P110446	79-09-4	<b>Propionic acid</b>	analytical standard	Agonist	Full agonist
Glucocorticoid receptor	P116562	53-03-2	<b>Prednisone</b>	98%	Agonist	Full agonist
Vitamin D receptor	P126516	131918-61-1	<b>Paricalcitol</b>	≥99%	Agonist	Agonist
DP <sub>1</sub> receptor	P129960	745-65-3	<b>Prostaglandin E1</b>	≥98%(HPLC)	Agonist	Full agonist
EP <sub>1</sub> ,EP <sub>2</sub> ,EP <sub>3</sub> ,EP <sub>4</sub> receptor	P129960	745-65-3	<b>Prostaglandin E1</b>	≥98%(HPLC)	Agonist	Full agonist
IP receptor	P129960	745-65-3	<b>Prostaglandin E1</b>	≥98%(HPLC)	Agonist	Full agonist
GPR119	P130493	17364-16-8	<b>1-Palmitoyl-sn-glycero-3-phosphocholine</b>	>99%	Agonist	Agonist
DP <sub>1</sub> ,DP <sub>2</sub> receptor	P275004	60203-57-8	<b>Prostaglandin J2</b>	≥95%	Agonist	Full agonist
DP <sub>1</sub> ,DP <sub>2</sub> receptor	P275206	41598-07-6	<b>Prostaglandin D2</b>	≥99%	Agonist	Full agonist
EP <sub>1</sub> ,EP <sub>2</sub> ,EP <sub>3</sub> ,EP <sub>4</sub> receptor	P275206	41598-07-6	<b>Prostaglandin D2</b>	≥99%	Agonist	Full agonist
FP receptor	P275206	41598-07-6	<b>Prostaglandin D2</b>	≥99%	Agonist	Full agonist
EP <sub>1</sub> ,EP <sub>2</sub> ,EP <sub>3</sub> receptor	P336631	38315-43-4	<b>17-Phenyl-trinor-prostaglandin E<sub>2</sub></b>	98%	Agonist	Full agonist
EP <sub>4</sub> receptor	P336631	38315-43-4	<b>17-Phenyl-trinor-prostaglandin E<sub>2</sub></b>	98%	Agonist	Agonist
DP <sub>1</sub> ,DP <sub>2</sub> receptor	P339275	87893-54-7	<b>Δ12-PGJ2 (Δ12-Prostaglandin J2)</b>	A solution in methyl acetate,98%	Agonist	Full agonist
Retinoid X receptor-α	P348349	14721-66-5	<b>Phytanic Acid</b>	A solution in ethanol, >96%	Agonist	Agonist
Peroxisome proliferator-activated receptor-α	P348795	1189-37-3	<b>Pristanic acid solution</b>	Solution in Ethanol (10mg/ml)	Agonist	Agonist
Peroxisome proliferator-activated receptor-α	R106321	302-79-4	<b>Retinoic acid</b>	analytical standard	Agonist	Full agonist
RAR-related orphan receptor-β	R106321	302-79-4	<b>Retinoic acid</b>	analytical standard	Agonist	Agonist
Retinoic acid receptor-α,β,γ	R106321	302-79-4	<b>Retinoic acid</b>	analytical standard	Agonist	Agonist
Testicular receptor 4	R106321	302-79-4	<b>Retinoic acid</b>	analytical standard	Agonist	Full agonist
TLX	R106321	302-79-4	<b>Retinoic acid</b>	analytical standard	Agonist	Agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
GPR84	R133494	5561-87-5	(±)-3-Hydroxydecanoic acid	≥98%	Agonist	Full agonist
chemerin receptor 1	R331811	1309610-43-2	Resolvin E1 Sodium Salt	-	Agonist	Full agonist
FPR2/ALX	R341442	872993-05-0	Resolvin D1	A solution in ethanol, ≥95%	Agonist	Full agonist
GPR32	R341442	872993-05-0	Resolvin D1	A solution in ethanol, ≥95%	Agonist	Full agonist
FPR2/ALX	R342110	528583-91-7	17(R)-Resolvin D1	A solution in ethanol, ≥95%	Agonist	Full agonist
BLT1 receptor	R342349	82337-46-0	12(R)-HETE	50 µg/ml in ethanol	Agonist	Full agonist
GluN1,2A,2B,2C,2D	S105977	312-84-5	D-Serine	>98.5%	Agonist	Agonist
CaS receptor	S113079	71-44-3	Spermine	for cell culture, ≥98.0%(GC)	Agonist	Full agonist
GPR12	S113079	1670-26-4	Sphingosylphosphorylcholine	>99%	Agonist	Full agonist
GPRC6 receptor	S137887	56-45-1	L-Serine	from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%	Agonist	Full agonist
HCA <sub>1</sub> receptor	S161106	10326-41-7	D-Lactic Acid	>90.0%(T)	Agonist	Partial agonist
HCA <sub>2</sub> receptor	S161108	300-85-6	DL-3-Hydroxybutyric Acid (contains Polymolecular esterification product)	>80.0%(T)	Agonist	Full agonist
mGlu <sub>4</sub> ,mGlu <sub>7</sub> receptor	S161191	407-41-0	L-O-Phosphoserine	>98.0%(T)	Agonist	Agonist
mGlu <sub>4</sub> ,mGlu <sub>6</sub> ,mGlu <sub>7</sub> ,mGlu <sub>8</sub> receptor	S161191	407-41-0	L-O-Phosphoserine	>98.0%(T)	Agonist	Full agonist
mGlu <sub>3</sub> receptor	S303409	3106-85-2	Spaglamic Acid	98%	Agonist	Full agonist
GPR119	S351349	111-57-9	Stearoyl Ethanolamide	>98%	Agonist	Full agonist
succinate receptor	S431423	110-15-6	Succinic acid	for synthesis	Agonist	Full agonist
GPRC6 receptor	S432937	56-41-7	(S)-(+)-Alanine	for synthesis	Agonist	Full agonist
mGlu <sub>1</sub> ,mGlu <sub>2</sub> ,mGlu <sub>3</sub> ,mGlu <sub>4</sub> ,mGlu <sub>5</sub> ,mGlu <sub>6</sub> ,mGlu <sub>7</sub> ,mGlu <sub>8</sub> receptor	S432951	56-86-0	(S)-(+)-Glutamic acid	for synthesis	Agonist	Agonist
mGlu <sub>1</sub> ,mGlu <sub>2</sub> ,mGlu <sub>3</sub> ,mGlu <sub>4</sub> ,mGlu <sub>5</sub> ,mGlu <sub>6</sub> ,mGlu <sub>7</sub> ,mGlu <sub>8</sub> receptor	S432951	56-86-0	(S)-(+)-Glutamic acid	for synthesis	Agonist	Full agonist
GPR119	S465645	19420-57-6	1-Stearoyl-sn-glycero-3-phosphocholine	≥99%, powder	Agonist	Agonist
Liver X receptor-α, Liver X receptor-β	S491757	77058-74-3	24(S),25-epoxycholesterol	98%	Agonist	Agonist
5-HT <sub>1B</sub> ,5-HT <sub>1D</sub> ,5-HT <sub>1E</sub> ,5-HT <sub>1F</sub> ,5-HT <sub>2A</sub> ,5-HT <sub>2B</sub> ,5-HT <sub>2C</sub> ,5-HT <sub>6</sub> ,5-HT <sub>7</sub> receptor	T101154	61-54-1	Tryptamine	98%	Agonist	Full agonist
Androgen receptor	T101368	57-85-2	Testosterone Propionate Solution	98%	Agonist	Agonist
Androgen receptor	T102170	57-85-2	Testosterone Solution	98%, for cell culture	Agonist	Agonist

# Agonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
TA <sub>1</sub> receptor	T105543	51-67-2	Tyramine	98%	Agonist	Agonist
TA <sub>1</sub> receptor	T105543	51-67-2	Tyramine	98%	Agonist	Full agonist
Thyroid hormone receptor- $\alpha,\beta$	T106193	51-48-9	L-Thyroxine	98%	Agonist	Agonist
GPR139	T118579	73-22-3	L-Thyroxine	from non-animal source, meets EP, JP, USP testing specifications, for cell culture, 99.0-101.0%	Agonist	Agonist
Thyroid hormone receptor- $\alpha,\beta$	T124580	51-24-1	3,3',5-Triiodothyroacetic acid	90%	Agonist	Agonist
DP <sub>1</sub> ,DP <sub>2</sub> receptor	T136386	551-11-1	tromethamine	≥95.0%	Agonist	Full agonist
EP <sub>1</sub> ,EP <sub>2</sub> ,EP <sub>3</sub> ,EP <sub>4</sub> receptor	T136386	551-11-1	tromethamine	≥95.0%	Agonist	Full agonist
FP receptor	T136386	551-11-1	tromethamine	≥95.0%	Agonist	Full agonist
TP receptor	T136386	551-11-1	tromethamine	≥95.0%	Agonist	Full agonist
Thyroid hormone receptor- $\alpha,\beta$	T162132	6893-02-3	3,3',5-Triiodo-L-thyronine	>98.0%(HPLC)	Agonist	Agonist
Pregnane X receptor	T336731	547-96-6	Trihydroxycoprostone	-	Agonist	Agonist
LPA5 receptor	T349619	15416-91-8	trans,trans-Farnesyl monophosphate ammonium salt	-	Agonist	Agonist
Glycine Receptor (All subtypes)	T431354	107-35-7	Taurine	Ultrapure BioReagent, ≥99.5% (T)	Agonist	Agonist
GPR84	U109482	112-37-8	Undecanoic acid	analytical standard, >99.5%(GC)	Agonist	Agonist
GPR17	U407337	2956-16-3	UDP-Gal	98%	Agonist	Agonist
P2Y <sub>14</sub> receptor	U407337	2956-16-3	UDP-Gal	98%	Agonist	Full agonist
GPR17	U407346	133-89-1	UDP-G	-	Agonist	Agonist
P2Y <sub>14</sub> receptor	U407346	133-89-1	UDP-G	-	Agonist	Full agonist
FFA2,FFA3 receptor	V108269	109-52-4	Valeric acid	Standard for GC, ≥99.5%(GC)	Agonist	Full agonist
Testicular receptor 4	V111674	68-26-8	Retinol	95%	Agonist	Full agonist
GPR55	V341165	287937-12-6	Virodhamine	98%	Agonist	Agonist
HCA <sub>3</sub> receptor	X139091	617-73-2	(±)-2-Hydroxyoctanoic acid	≥98%	Agonist	Full agonist
GPR119,55	Z130746	111-58-0	N-Oleylethanolamine	>98%	Agonist	Agonist
Peroxisome proliferator-activated receptor- $\alpha$	Z130746	111-58-0	N-Oleylethanolamine	>98%	Agonist	Agonist



# Allosteric modulator

Target	Cat.No	CAS	Product Name	Specification	Type	Action
5-HT <sub>3A</sub>	E111989	64-17-5	Ethanol	Analytical Reagent, water ≤ 0.3%	Allosteric modulator	Positive
5-HT <sub>7</sub> receptor	O105240	301-02-0	Oleamide	70%	Allosteric modulator	Negative
CaS receptor	T118579	73-22-3	L-Tryptophan	from non-animal source, meets EP, JP, USP testing specifications, for cell culture, 99.0-101.0%	Allosteric modulator	Positive
GABA <sub>A</sub> receptor α1,α2,α3,α4,α5, α6 subunit	A136640	516-54-1	ALLOPREGNAN-3ALPHA-OL-20-ONE	98%	Allosteric modulator	Potentiation
GABA <sub>A</sub> receptor α1,α2,α3,α4,α5, α6 subunit	T346425	567-03-3	Tetrahydro 11-Deoxycorticosterone	-	Allosteric modulator	Potentiation
Glycine Receptor (All subtypes)	E111989	64-17-5	Ethanol	Analytical Reagent, water ≤ 0.3%	Allosteric modulator	Potentiation
glycine receptor α1 subunit	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Allosteric modulator	Potentiation

# Antagonist

Target	Cat.No	CAS	Product Name	Specification	Type	Action
5-HT <sub>2B</sub> receptor	M118674	73-31-4	Melatonin	98%	Antagonist	Antagonist
Estrogen-related receptor-α,β,γ	D109025	56-53-1	Diethylstilbestrol	99%	Antagonist	Antagonist
FPR1	C104903	474-25-9	Chenodeoxycholic acid	analytical standard	Antagonist	Antagonist
FPR1	D103698	83-44-3	Deoxycholic acid	analytical standard, >99%	Antagonist	Antagonist
LPA <sub>2</sub> ,LPA <sub>3</sub> ,LPA <sub>4</sub> receptor	T349619	15416-91-8	trans,trans-Farnesyl monophosphate ammonium salt	-	Antagonist	Antagonist
Mineralocorticoid receptor	P106427	57-83-0	Progesterone	USP grade	Antagonist	Antagonist
P2Y <sub>1</sub> receptor	A334867	1053-73-2 (free acid)	Adenosine 3',5'-Bisphosphate Dicalcium Hydrate	-	Antagonist	Antagonist
P2Y <sub>1</sub> ,P2Y <sub>4</sub> receptor	A501266	56-65-5	Adenosine triphosphate	90%	Antagonist	Antagonist
RAR-related orphan receptor-β	R106321	302-79-4	Retinoic acid	analytical standard	Antagonist	Antagonist

# Channel blocker

Target	Cat.No	CAS	Product Name	Specification	Type	Action
Ca <sub>v</sub> 3.1,3.2,3.3	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Channel blocker	Antagonist
K <sub>2p</sub> 3.1	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Channel blocker	Inhibition
K <sub>2p</sub> 3.1	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Channel blocker	Others
K <sub>2p</sub> 3.1	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Channel blocker	Others
K <sub>Ca</sub> 2.12.3	S416439	124-20-9	Spermidine	97%	Channel blocker	Antagonist
KCa2.1,2,3	S113079	71-44-3	Spermine	for cell culture, ≥98.0%(GC)	Channel blocker	Antagonist
K <sub>v</sub> 1.2	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Channel blocker	Pore blocker
K <sub>v</sub> 2.1	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Channel blocker	Others
K <sub>v</sub> 4.2	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Channel blocker	Others
Maxi Cl <sup>-</sup>	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Channel blocker	Others
TRPC5	P106427	57-83-0	Progesterone	USP grade	Channel blocker	Inhibition
TRPM4	A501266	56-65-5	Adenosine triphosphate	90%	Channel blocker	Antagonist
TRPM4,5,7	S113079	71-44-3	Spermine	for cell culture, ≥98.0%(GC)	Channel blocker	Antagonist
TRPM4	A108808	58-61-7	Adenosine	Ultra pure,99.5%	Channel blocker	Others
TRPM7	D130604	123-78-4	D-erythro-sphingosine	>99%	Channel blocker	Inhibition
TRPM8	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Channel blocker	Others
TRPM8	L100446	60-33-3	Linoleic acid	analytical standard, ≥99.0%(GC)	Channel blocker	Others
TRPV3	R342110	528583-91-7	17(R)-Resolvin D1 (copy)	A solution in ethanol, ≥95%	Channel blocker	Inhibition
VRAC	A111764	506-32-1	Arachidonic acid	analytical standard, ≥99.0%(GC)	Channel blocker	Others

# Gating inhibitor

Target	Cat.No	CAS	Product Name	Specification	Type	Action
CNGA2	A122355	116-31-4	all trans-Retinal	≥98%	Gating inhibitor	Antagonist
K <sub>Ca</sub> 2.1	O341917	1716-06-9	Oleoyl coenzyme A	≥92%	Gating inhibitor	Antagonist
K <sub>ir</sub> 6.1,6.2	A501266	56-65-5	Adenosine triphosphate	90%	Gating inhibitor	Antagonist
K <sub>Na</sub> 1.2	A501266	56-65-5	Adenosine triphosphate	90%	Gating inhibitor	Others
TRPA1	M105139	89-78-1	DL-Menthol	analytical standard	Gating inhibitor	Antagonist
TRPA1	R341442	872993-05-0	Resolvin D1	A solution in ethanol, ≥95%	Gating inhibitor	Inhibition

# Inhibitor

Target	Cat.No	CAS	Product Name	Specification	Type	Action
Sodium/bile acid and sulphated solute cotransporter 1	U110696	128-13-2	Ursodeoxycholic acid	analytical standard	Inhibitor	Inhibition
vitamin K epoxide reductase complex subunit 1	C432837	5300-03-8	9-cis-Retinoic acid	≥98% (HPLC)	Inhibitor	Inhibition

# Subunit-specific

Target	Cat.No	CAS	Product Name	Specification	Type	Action
Glycine Receptor (All subtypes)	D106380	53-43-0	trans-Dehydroandrosterone	99%	Subunit-specific	Inhibition
Glycine Receptor (All subtypes)	P106427	57-83-0	Progesterone	USP grade	Subunit-specific	Inhibition
Glycine Receptor (All subtypes)	A274932	94421-68-8	Anandamide (ethanol solution)	≥98%	Subunit-specific	Potentialiation
Glycine Receptor (All subtypes)	P129412	145-13-1	Pregnenolone	≥98%(GC)	Subunit-specific	Potentialiation

# Others

Target	Cat.No	CAS	Product Name	Specification	Type	Action
ABC11	G304255	640-79-9	Glycochenodeoxycholic acid	>98%	Others	Binding



**METABOLISM**

**aladdin<sup>®</sup>**

**Aladdin Scientific Corporation**

Official website: [www.aladdinsci.com](http://www.aladdinsci.com)

Phone: +1 (833) 552-7181

Email for purchasing: [sales@aladdinsci.com](mailto:sales@aladdinsci.com)

Email for customer service: [custserv@aladdinsci.com](mailto:custserv@aladdinsci.com)

Email for technical support: [support@aladdinsci.com](mailto:support@aladdinsci.com)

Submit a ticket: <https://www.aladdinsci.com/customersupport>

Address: 14078 Meridian Parkway, Riverside, CA. 92518 USA

